anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ventricular tachycardia (VT) is a life-threatening arrhythmia which occurs frequently in the setting of structural heart disease, most often as result of myocardial fibrosis or scar. Catheter ablation is often performed to treat recurrent VT, but is predicated on precise localization of myocardial scar, as scar is often the source of VT. Currently during VT ablation procedures the identification of scar is based on electroanatomic mapping where bipolar voltage criteria have been established (i.e., bipolar electrogram voltage \< 1.5 mV is considered scar). However this definition is purely based on electrical signal information and so has significant limitations: 1) there has not been definitive establishment of the sensitivity and specificity of this threshold for defining scar in comparison with tissue; 2) a detailed 3-D map created by time-consuming movement of the mapping catheter must be obtained in order to assess the existence and location of the scar; 3) only scar on the surface in contact with the mapping catheter (most often endocardial) may be definitively identified, whereas there may be intramyocardial or epicardial scar that would not be identified unless the mapping catheter makes direct contact with those areas which may involve additional risky access (epicardial) or even impossible (intramyocardial). For these reasons it would be very helpful to have another method to identify and localize myocardial scar during a VT ablation procedure. Cardiac MRI has been validated for identifying and localizing scar, but would not be recommended for many patients due to presence of ICD (implantable cardioverter-defibrillator) devices in these patients. Contrast-enhanced echocardiography has been validated to identify myocardial scar (Montant 2010), and intracardiac echocardiography (ICE) is standardly used in VT ablation procedures. Therefore, the investigators will assess the utility of contrast enhanced ICE by identifying and localizing myocardial scar real-time during VT ablation procedures.
PURPOSE: Are embryo culture conditions, including type of incubator, oxygen tension, and culture media, associated with obstetric or neonatal complications following in vitro fertilization (IVF)?
METHODS: A systematic search of MEDLINE, EMBASE, and Cochrane Library was performed from January 01, 2008, until October 31, 2021. The studies reporting quantitative data on at least one of the primary outcomes (birthweight and preterm birth) for the exposure group and the control group were included. For oxygen tension, independent meta-analysis was performed using Review Manager, comparing hypoxia/normoxia. For culture media, a network meta-analysis was carried out using R software, allowing the inclusion of articles comparing two or more culture media.
RESULTS: After reviewing 182 records, 39 full-text articles were assessed for eligibility. A total of 28 studies were kept for review. Meta-analysis about the impact of incubator type on perinatal outcomes could not be carried out because of a limited number of studies. For oxygen tension, three studies were included. The pairwise meta-analysis comparing hypoxia/normoxia did not show any statistical difference for birthweight and gestational age at birth. For culture media, 18 studies were included. The network meta-analysis failed to reveal any significant impact of different culture media on birthweight or preterm birth.
CONCLUSION: No difference was observed for neonatal outcomes according to the embryo culture conditions evaluated in this review. Further research is needed about the safety of IVF culture conditions as far as future children's health is concerned.
PROBLEM TO BE SOLVED: To provide the subject composition containing a bonded product and/or a complex of a concentrated and/or purified virus and a neutralizing antibody, effective for promoting the immunocompetence of human and animal and imparting with sufficient protecting capability against viruses having high mutation degree. SOLUTION: This pharmaceutical composition for the prevention and/or treatment of viral diseases caused by viruses having high mutation degree or existing in various genetic patterns and/or sub-types is produced by using a bonded material or a complex containing (A) a concentrated and/or purified virus or its fragment and (B) a neutralizing antibody. The purification of virus is preferably carried out e.g. by filtration with a nano-filter. The neutralizing antibody is preferably a phylactic antibody originated from plasma or a plasma fraction. The objective composition is suitable for intravenous injection, transmucous administration, etc. The composition is preferably used for the prevention of viral hepatitis type C among viral diseases.
Water-soluble film or solid gel with healing activity comprising: . a) between 25 and 60% by weight of sodium alginate, as main filmogenous substance, . b) between 0.1 and 20% by weight of microcrystalline cellulose over the total weight of the film, . c) between 0.1 and 25% by weight of vegetable proteins, . d) at least one glycosaminoglycan and/or galactosaminoglycan sulphate of the natural type, as active ingredient with healing activity and a device for medical use in particular for topical applications, containing said water-soluble film. This device is in particular suitable for covering sores and wounds, even large ones, protecting them from the external environment, continuously providing glycosaminoglycan sulphate and/or galactosaminoglycan sulphate of the natural type in the area of the damaged skin. An organic hydroxy acid can be added to accelerate the wound healing.
PURPOSE:To isolate HBe antigen by adsorbing antigens relating to hepatitis B virus in plasma on an adsorbent and treating with an eluent. CONSTITUTION:Antigens relating to hepatitis B virus (HBeAg) in plasma are adsorbed on an adsorbent (the volume ratio of the plasma to the adsorbent is 10-50) and treated with an eluent to isolate HBeAg. The adsorbent is a variety of porous materials such as sintered calcium phosphate, for example, hydroxy-apatite, tricalcium diphosphate, solid acid such as silica-alumina, cation- exchange resin such as IRC-84. A practical adsorbent has particle sizes of 20-60 mesh. The eluent is preferably, for example, sodium chloride solution, aqueous surfactant solution, aqueous sodium deoxybile acid. The isolated HBeAg is further subjected pretreatment and used as a starting substance for production of vaccine.
Expression of VEGF correlates with clinically aggressive, tamoxifen resistant metastatic breast cancers. To assess the role of VEGF expression on breast cancer growth, metastasis and development of anti-estrogen resistance, and desmoplasia an ER-positive, several MCF-7-derived cell lines, designated C9V, were engineered to express VEGF in a doxycycline-regulated manner. C9V cells were introduced into a athymic nude mouse to produce a xenograft model of breast cancer. Expression of VEGF in xenografts increased neoangiogenesis, enhanced tumor growth, stimulated a tamoxifen resistant phenotype, increased metastatic potential and induced a desmoplastic response. These results suggest that inhibition of VEGF expression or action will be effective in the treatment of breast cancer. In addition, inhibition of VEGF expression or action with inhibition of estrogen expression or action may also be effective.
PURPOSE:To obtain the titled composition for remedy by containing blood collected from living body having malignant tumor, etc., with a solution of an inorganic salt or an organic salt having a concentration higher than a specific level and to carry out the titled treatment by introducing the composition into the same or the same kind of living body. CONSTITUTION:Blood collected from a living body carrying malignant tumor, etc., is made to contact with an aqueous solution of an inorganic salt (e.g. NaCl or KCl) or an organic salt (e.g. sodium citrate or potassium acetate) having a concentration of >=0.3M (preferably 0.5-2.0M) to obtain the remedying composition for malignant tumor, etc., composed of the treated blood. The composition is injected into the same or the same kind of living body as the above body. The blood treatment can be carried out without using the separation of plasma, etc., and, in some cases, without necessitating a dialyzer and a dilution apparatus. Accordingly the operation time can be shortened. Malignant tumor, etc., can be rapidly necrosed or diminished by the administration of the above treated blood to a living body.
Monoclonal antibodies targeting type 2 inflammation are promising treatments for eosinophilic-associated diseases. There is growing interest in the potential benefits of combining two biologics to treat patients with poorly controlled conditions. We present a case of a 54-year-old female patient affected with a relapsing-refractory ANCA myeloperoxidase positive eosinophilic granulomatosis with polyangiitis (EGPA), presenting with difficult-to-treat asthma and rhino-sinusitis manifestations. She failed several biologics, including omalizumab 300 mg, mepolizumab 100 mg, and benralizumab 30 mg every 8 weeks. A switch to dupilumab led to significant eosinophilia (7.69 × 109/L) as well as systemic symptoms, and a deterioration of asthma control. Therefore, a combination of dupilumab-benralizumab was started, leading to better nasal and ear outcomes, asthma control and decrease in blood eosinophils. During the 12-month treatment, no adverse effects were observed. We conducted an extensive literature search in MEDLINE for original articles published until August 1st, 2023 reporting the combination of anti-type 2 biologics. A total of 51 cases were retrieved from the literature. Omalizumab was the most frequently combined drugs (34 cases). Combination therapy led to reduction of asthma exacerbations and glucocorticoid intake, though was ineffective only for one EGPA patient. Only one patient on omalizumab-mepolizumab therapy reported a mild adverse reaction. Combination biologic therapies for conditions which share pathogenic pathways appears to be both safe and effective. This approach may benefit patients with uncontrolled conditions and counter side effects of biologics, like dupilumab-related hypereosinophilia.
The management of chronic myeloid leukemia (CML) diagnosed during pregnancy is a rare and challenging situation. We report the treatment and outcome of 87 cases diagnosed in chronic phase from 2001-2022 derived from the largest international observational registry, supported by the European LeukemiaNet (ELN), of 400 pregnancies in 299 CML women. Normal childbirth occurred in 76% without an increased rate of birth abnormalities or life-threatening events, including in patients untreated or treated with interferon-α and/or imatinib in 2nd-3rd trimester. The low birth weight rate of 12% was comparable to that seen in the normal population. Elective and spontaneous abortions occurred in 21% and 3%, respectively. The complete hematologic response rate before labor was 95% with imatinib and 47% with interferon only. No disease progression during pregnancy was observed, 28% of the patients switched their therapy at varying times after delivery. Treatment options balance the efficacy and safety for mother and infant: interferon-α can commence in the 1st trimester and continued throughout in cases of good disease control and tolerability. Because of limited placental crossing, selected tyrosine kinase inhibitors (imatinib and nilotinib) seem to be safe and effective options in 2nd and 3rd trimester while hydroxycarbamide offers few benefits.
Participants will receive a supply of mixed nuts containing: 1 Brazil nut (\~3g), walnuts (15g), hazelnuts (7g), and almonds (7g) to be consumed daily for 90 days. They will also receive dietary counselling on how to follow the Australian Dietary Guidelines.
Annexin A1 (AnxA1) is a glucocorticoid-inducible protein and an important endogenous modulator of inflammation. However, its effect in the endometrial microenvironment is poorly explained. This study aimed to evaluate the role of endogenous AnxA1 in an endometritis mouse model induced by lipopolysaccharide (LPS). Female C57BL/6 wild-type (WT) and AnxA1-/- mice were divided into two groups: SHAM and LPS. To induce endometritis, mice received a vaginal infusion of 50 μL of LPS (1 mg/mL) dissolved in phosphate-buffered saline. After 24 h, the mice were euthanized, and blood and uteri samples were collected. The endometrium inflammatory scores were significantly increased in the LPS-treated group. AnxA1-/- mice from the LPS group demonstrated a significant increase in the number of degranulated mast cell levels compared to AnxA1-/- SHAM mice. The Western blotting analysis revealed that a lack of AnxA1 promoted the upregulation of NLRP3 and pro-IL-1β in the acute endometritis animal model compared to WT LPS animals. LPS-induced endometritis increased the number of blood peripheral leukocytes in both WT and AnxA1-/- mice compared with SHAM group mice (p < 0.001). AnxA1-/- mice also showed increased plasma levels of IL-1β (p < 0.01), IL-6, IL-10, IL-17, and TNF-α (p < 0.05) following LPS-induced endometritis. In conclusion, a lack of endogenous AnxA1 exacerbated the inflammatory response in an endometritis model via NLRP3 dysregulation, increased uterine mast cell activation, and plasma pro-inflammatory cytokine release.
Molindone Hydrochloride has a pharmacological profile in laboratory animals which predominantly resembles that of other antipsychotic agents causing reduction of spontaneous locomotion and aggressiveness, suppression of a conditioned response and antagonism of the bizarre stereotyped behavior and hyperactivity induced by amphetamines. In addition, Molindone Hydrochloride antagonizes the depression caused by the tranquilizing agent tetrabenazine.

In human clinical studies an antipsychotic effect is achieved in the absence of muscle relaxing or incoordinating effects. Based on EEG studies, Molindone Hydrochloride exerts its effect on the ascending reticular activating system.

Human metabolic studies show Molindone Hydrochloride Tablets to be rapidly absorbed and metabolized when given orally. Unmetabolized drug reached a peak blood level at 1.5 hours. Pharmacological effect from a single oral dose persists for 24 to 36 hours. There are 36 recognized metabolites with less than 2 to 3% unmetabolized Molindone Hydrochloride Tablets being excreted in urine and feces.
Sequence A: Patients will be observed without any intervention for eight weeks. Sequence B: Participants will receive warm acupuncture for 20 minutes twice a week for eight weeks.
In the Constant groups, incentive amounts will remain unchanged across time. The "High" group will receive incentives worth $16.
Surgical site infections (SSI) are a significant cause of morbidity and mortality worldwide, and particularly in low- and middle-income countries, where geographic and infrastructural barriers often delay or prevent post-operative patients from returning to care. In these settings, rates of SSI can reach 30%. In Rwanda, the current standard of care does not include follow-up of post-operative surgical patients. There, a network of community health workers (CHWs) is employed to provide care and follow-up for pregnant and post-partum women as well as children under five years of age. However, the limited education and existing work load of these workers preclude them from supporting the follow-up of other specialized conditions, such as post-operative patients.

The interventions evaluated in this proposed research seeks to address these gaps. The main aim is to evaluate the impact of the SSI screening protocol, delivered by sCHWs equipped with mHealth support, on the rate of return to care for patients with SSI 10 days post-operation. Two CHW-mHealth interventions will be evaluated. In the first, a sCHW will visit post-operative study participants in their homes to administer the screening protocol prompted by the mobile phone. In the second, a sCHW will call the patient and administer the same screening protocol over the phone. In this phase of the research, 364 patients will be assigned to each of these delivery arms, and the rates of appropriate return to care will be compared to that of 364 patients in a control arm receiving the standard of care (i.e. no additional follow-up). Process indicators also will be reported to describe the feasibility of CHW-mHealth interventions.

Investigators believe that the SSI screening protocol administered via CHW-mHealth interventions can support accurate diagnosis of SSI and refer patients back to the hospital for appropriate follow-up care. The research team's close collaboration with colleagues at the Rwanda Ministry of Health will facilitate the scale-up of the intervention, should it prove efficacious. Results of this study will also inform the development of similar mHealth interventions across other disease areas, allowing CHWs to expand services to other specialized patients in rural African settings.
Patient, user, and/or AI information are used in a multi-objective optimization to select one of a plurality of available AIs for a task. On a patient or user-specific basis, an optimal AI is selected and applied for medical imaging or other healthcare actions. The selection may be before application, avoiding costs of applying multiple AIs to obtain the best results. The optimization may be based on statistical feedback from the user for various of the available AIs, providing information not otherwise available. The optimization may be based on AI performance, AI inclusion and/or exclusion criteria, and/or pricing information. By using optimization based on various information related to the patient, user, and/or available AI, the application of AI for a given user and/or patient by the computer may be improved. The computer operates better to provide more focused information through AI application.
This laboratory has defined several mutations in muscle diseases which mimic idiopathic inflammatory myopathy, (IIM, polymyositis or dermatomyositis), in particular, phosphofructokinase (PFK) deficiency (Type VII glycogenosis) and acid maltase (GAA) deficiency (Type II glycogenosis). Some patients with each of these autosomal recessive diseases have been shown to be genetic compounds, with different mutations on the alleles from each parent. In this protocol, we seek permission to receive and perform genetic screening on samples of tissue, blood, or DNA from patients with known metabolic muscle diseases, their family members, patients with undiagnosed muscle diseases, and groups of control subjects. Although we will know the names and histories of the patients, and may choose to admit them under other protocols for further studies, the tests we propose to perform on their DNA are currently only of laboratory interest and we believe that the outcome has no implications for the clinical care of the subjects. We propose to obtain oral consent, as appropriate to take a limited history and to speak to the patient's physician, from those patients and family members we speak to directly. All specimens obtained in family studies of a particular disease (e.g., PFK deficiency or GAA deficiency) will be obtained after written consent and will be tested only for the genes of the particular disease under study. After completion of those tests, the DNA, or products derived from it will be stored only under code so that it may be used as a control sample for other studies.
The usual care group will consist of pregnant women who receive no experimental intervention but will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format, plus any additional clinic materials or oral information provided in conversation with clinicians (n= 375 total, 125 per site). We are transferring ACOG's prenatal screening education onto the electronic platform to control for any differences in attention that may be due to technology platform and to track time interacting with the material via the web portal.
Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
Biological relative of subjects with germline TP53 mutation or variant (LFS), including first degree (siblings, parents) and second degree (grandparents, aunts, uncles) relatives. Negative for germline TP53 mutation or variant. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a stool sample, as well as access to their residual clinical tissues.
Participant will receive a nasopharyngeal wash with sterile saline. The irrigation saline is recollected into the device's internal specimen chamber. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
HIV infection has been shown to increase mortality from tuberculosis (TB) fivefold in parts of Subsaharan Africa. Increasingly, HIV infected children in developing countries are becoming infected with Mycobacterium tuberculosis (Mtb) and dying at an early age. This project will evaluate novel approaches to the diagnosis of AIDS-related pediatric TB in a hyperendemic setting using rapid, cost-effective Mtb culture and susceptibility methods based on direct microscopic observation techniques. This study will utilize alternative noninvasive Mtb tests that are performed on nasopharyngeal aspirates (NPA) and stool. An optional component will assess improved rapid detection of Mtb by a semi-nested polymerase chain reaction assay (N2 PCR), a technique appropriate for regional reference laboratories in developing countries.

Two hundred-sixty children with clinically diagnosed pulmonary TB (including at least 100 HIV infected children) from the Hospital del Nino, Lima, Peru, and 260 age-matched controls will be enrolled in this study. Mtb will be detected in NPAs and stool by new and traditional culture methods and by N2 PCR. Gastric aspirates from children with a clinical diagnosis of TB will also be tested. Children with a positive N2 PCR but without clinical evidence of TB requiring antituberculous therapy will be followed longitudinally.
The compounds can be applied in medicine. They have the general formula ra-A-Het-B-Ar-E where A, B, Ar, Het and Ra have the meanings listed in the descripiton. When E is a cyanogroup the compounds are valuable intermediate products for making other compounds with the same general formula. In case E means RbNH-C(=NH)-group the compounds show valuable pharmaceological properties, in particular thrombin inhibition effect and thrombin time elongation effect. The invention also relates to tautomers, stereoisomers, mixtures and salts of the above compounds. 15 claims
<P>PROBLEM TO BE SOLVED: To provide a dropping preservation container which is prevented from contacting with outside air at a minimum.  <P>SOLUTION: A container 1, a dropping nozzle 2 and a pressurizing section 3 which pressurizes for drop of a fluid from the dropping nozzle 2 are installed. The dropping nozzle 2 comprises a base section 21 equipped with a dropping hole 20 in the center, a plurality of supplying slit-forming sections 22 located in a concentric fashion for forming approximately cylindrical supplying slits around the dropping hole 20, a floating valve 23 which moves up and down while constantly contacting with each ends of the supplying slit-forming sections 22, and a trunk 24 covering the supplying slit-forming sections 22 and the floating valve 23 around the outside of the base section 21. The trunk 24 comprises a locking section 25 which holds the floating valve 23 among the supplying slit-forming sections 22 by restricting its movement. Additionally, the base section 21, the supplying slit-forming sections 22 and the trunk 24 are composed as a unit by a resin. The pressurizing section 3 comprises a sealing member 30 which pressurizes the inside of the container.  <P>COPYRIGHT: (C)2007,JPO&INPIT